Raising Awareness of Lung Cancer Screening Through Social Media: An Interview With Aimee Strong, MSN, AGACNP-BC

​ Lung cancer screening using low-dose computed tomography (CT) has been endorsed by the United States Preventive Services Task Force and is covered by most insurances, yet this service is still underutilized, and some individuals at high risk for lung cancer may not know that it exists. Aimee Strong, MSN, AGACNP-BC, investigated whether social media could be used to educate high-risk individuals about lung cancer screening and motivate them to discuss screening with their health care providers....
Continue reading

FDA Expands Pembrolizumab Approval for NSCLC

Previously, pembrolizumab (Keytruda®, Merck Inc.) was approved as a single agent for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 with a tumor proportion score (TPS)  greater than or equal to 50%. The FDA has now expanded approval for first-line pembrolizumab to include patients with stage III NSCLC who do not qualify for surgical resection or definitive chemoradiation or metastatic NSCLC. For patients to qualify for tre...
Continue reading

Not Just Humankind’s Best Friend: Dogs Can Sniff Out Cancer

With 300 million olfactory receptors in their noses—50 times more than humans—dogs can smell scents that humans cannot even perceive. Researchers now report that this sniffing capability allows dogs to distinguish between blood samples of patients with cancer and blood samples of healthy individuals. For the study, presented at the American Society for Biochemistry and Molecular Biology: Experimental Biology Meeting 2019, four 2-year-old beagle dogs were trained by operant conditioning to use th...
Continue reading

Centrally Located NSCLC: Stereotactic Body Radiotherapy Is Safe

​ A phase 1/2 clinical trial reports that stereotactic body radiotherapy (SBRT) is well tolerated by patients with centrally located early-stage non-small cell lung cancer (NSCLC). A high-dose ablative radiotherapy, SBRT is a standard, generally well-tolerated treatment for patients with inoperable, node-negative NSCLC. It has not previously been studied in patients with centrally located early-stage NSCLC because these patients are at increased risk of experiencing toxicity from high-dose ablat...
Continue reading

An Alternative to Biopsy: Improved CTC Collection Method

​ Researchers at the University of Michigan have developed a prototype of a wearable device that can continuously collect circulating tumor cells (CTCs) directly from a patient's bloodstream. The investigators hope that this device, which has thus far proven successful in canine models, could ultimately be used as an alternative to biopsies. Circulating tumor cells, which circulate through lymphatic channels and blood after they are shed from the primary tumor, are the basis for cancer metastase...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.